Mati Therapeutics Inc.

Patients are needlessly losing vision from glaucoma because they have difficulty taking daily eye drops. This technology potentially replaces eye drops.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Austin, Texas, US
  • Currency USD
  • Founded 2012
  • Employees 7
  • Website matitherapeutics.com

Company Summary

Mati is developing a sustained ocular drug delivery platform with the first target a 90 day release of glaucoma drug latanoprost. This is a combination drug/device using a small device that goes into the tear duct of the eye and is designed to stay there, delivering drug, over a 90 day period. The technology can be viewed as an alternative for eye drops and has completed Phase II testing in 570 US patients.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free